Gal‐3 inhibitors have emerged as a promising class of therapeutic agents, particularly for treating neoplastic diseases.[13, 14, 15, 16] Given its pivotal role in orchestrating pathways that promote fibrosis and tumorigenesis, there has been a concerted effort to identify compounds capable of precisely targeting Gal‐3 activity. Here, LGALS3 is linked to neoplasm.